Hiromu Habashita - Ono Pharmaceutical Executive Officer, Chief Director of Research
| OPHLF Stock | USD 11.03 1.47 11.76% |
Director
Hiromu Habashita is Executive Officer, Chief Director of Research of Ono Pharmaceutical Co
| Phone | 81 6 6263 5670 |
| Web | https://www.ono-pharma.com |
Ono Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.1204 % which means that it generated a profit of $0.1204 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1605 %, meaning that it generated $0.1605 on every $100 dollars invested by stockholders. Ono Pharmaceutical's management efficiency ratios could be used to measure how well Ono Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Ann Fudge | Novartis AG ADR | 70 | |
| Graham Chipchase | AstraZeneca PLC ADR | 54 | |
| Nazneen Rahman | AstraZeneca PLC ADR | N/A | |
| Frans Houten | Novartis AG ADR | 61 | |
| Andreas Planta | Novartis AG ADR | 65 | |
| Elizabeth Doherty | Novartis AG ADR | 64 | |
| Marc Dunoyer | AstraZeneca PLC ADR | 72 | |
| Karen Vousden | Bristol Myers Squibb | 63 | |
| Bridgette Heller | Novartis AG ADR | 59 | |
| Deborah DiSanzo | AstraZeneca PLC ADR | 59 | |
| Theodore Samuels | Bristol Myers Squibb | 66 | |
| Simon Moroney | Novartis AG ADR | 62 | |
| Dinesh Paliwal | Bristol Myers Squibb | 63 | |
| Philip Broadley | AstraZeneca PLC ADR | 52 | |
| Matthew Emmens | Bristol Myers Squibb | 68 | |
| Genevieve Berger | AstraZeneca PLC ADR | 64 | |
| Julia Haller | Bristol Myers Squibb | 66 | |
| Robert Bertolini | Bristol Myers Squibb | 58 | |
| Sherilyn McCoy | AstraZeneca PLC ADR | 60 | |
| Ton Buechner | Novartis AG ADR | 55 | |
| Manuel Medina | Bristol Myers Squibb | 53 | |
Management Performance
| Return On Equity | 0.16 | |||
| Return On Asset | 0.12 |
Ono Pharmaceutical Leadership Team
Elected by the shareholders, the Ono Pharmaceutical's board of directors comprises two types of representatives: Ono Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ono. The board's role is to monitor Ono Pharmaceutical's management team and ensure that shareholders' interests are well served. Ono Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ono Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gyo Sagara, CEO and President and Representative Director | ||
| Hiromu Habashita, Executive Officer, Chief Director of Research | ||
| Katsuji Teranishi, Head of Marketing Strategy Planning, Deputy Director of Sales and Marketingl and Corporate Officer | ||
| Toshihiro Tsujinaka, Executive Officer, Senior Director of Oncology in Main Sales Unit | ||
| Shozo Matsuoka, Executive Officer, Manager of R & D Strategy Office | ||
| Kiyoaki Idemitsu, Exec Officer | ||
| Hiroshi Ichikawa, Sr. Director of Metropolitan Area Management and Metropolitan Area First Branch and Corporate Officer | ||
| Isao Ono, Executive Officer, Manager of Environmental Management Office, Director | ||
| Yukio Tani, Executive Officer, Director of Public Relations | ||
| Toichi Takino, Executive Director of Corporate Devel. and Strategy and Corporate Officer |
Ono Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Ono Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.16 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.26 % | |||
| Operating Margin | 0.35 % | |||
| Current Valuation | 11.13 B | |||
| Shares Outstanding | 488.31 M | |||
| Shares Owned By Insiders | 16.04 % | |||
| Shares Owned By Institutions | 44.41 % | |||
| Price To Earning | 18.12 X | |||
| Price To Book | 2.29 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Ono Pink Sheet
Ono Pharmaceutical financial ratios help investors to determine whether Ono Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ono with respect to the benefits of owning Ono Pharmaceutical security.